Table 2.
Baseline characteristics of the participants of the study
| Variables | Placebo (n=40) | LN18178-200 (n=40); P-value | LN18178-400 (n=40); P-value |
|---|---|---|---|
| Age (y) | 45.90 ± 6.28 | 43.66 ± 5.81; 0.2893 | 45.20 ± 5.46; 0.8615 |
| Body weight (kg) | 73.99 ± 8.25 | 75.26 ± 8.73; 0.7809 | 73.37 ± 8.00; 0.9412 |
| BMI (kg/m2) | 26.11 ± 1.98 | 25.96 ± 1.85; 0.9508 | 25.56 ± 2.28; 0.4664 |
| AMS score | 36.45 ± 4.02 | 35.58 ± 4.54; 0.6406 | 35.13 ± 4.24; 0.3501 |
| Grip strength (Kg) | 35.85 ± 11.25 | 35.56 ± 12.95; 0.9942 | 35.11 ± 13.16; 0.9625 |
| PSS-10 score | 19.90 ± 5.15 | 20.39 ± 5.25; 0.9092 | 19.60 ± 5.36; 0.9647 |
| Free Testosterone (pmol/L) | 42.68 ± 10.62 | 41.64 ± 13.39; 0.9949 | 40.95 ± 11.56; 0.9433 |
| Total Testosterone (nmol/L) | 12.62 ± 4.84 | 12.48 ± 5.47; 0.9997 | 13.69 ± 5.13; 0.4930 |
| Dihydrotestosterone (nmol/L) | 2.22 ± 0.77 | 2.25 ± 0.90; 0.7981 | 2.20 ± 0.93; 0.9940 |
| Cortisol (nmol/L) | 207.55 ± 79.10 | 198.44 ± 52.69; 0.8082 | 221.90 ± 98.26; 0.7033 |
| Estradiol (pmol/L) | 90.86 ± 35.29 | 95.05 ± 30.45; 0.8557 | 91.46 ± 35.90; 0.9966 |
Data present as mean ± SD; Intent-to-treat (ITT) population. No significant differences between the placebo and the LN18178 groups;
Data were analyzed using ANOVA.